


wherein:

- (i)  $R_1$  represents an unsubstituted  $C_6$  or  $C_{10}$  aryl group; or a  $C_6$  aryl group substituted with Me or OMe;
- (ii) A represents O, S; or a sulfur atom oxidized to sulfoxide;
- (iii) the cyclic group labeled F represents an unsubstituted  $C_6$  or  $C_{10}$  aryl or a  $C_5$  heteroaryl group (nitrogen as heteroatom) or a phenyl substituted with ethoxycarbonyl function; and
- (iv) Y represents the group



wherein  $R_2$  and  $R_3$  are independently hydrogen; or methyl or ethyl;  
or Y represents the group  $\text{CH}_3$ , or  $(\text{CH}_2)_2\text{CH}_3$ , or an unsubstituted  $C_5$  heteroaryl group (nitrogen as heteroatom); and  
further comprising an inert carrier.

21. A pharmaceutical composition according to claim 20, wherein  $R_1$  is an unsubstituted 1-naphthyl.

22. A pharmaceutical composition according to claim 20, wherein F is an unsubstituted phenyl group or an unsubstituted naphthyl or 2,3-pyridine.


23. A pharmaceutical composition according to claim 20, wherein  $R_1$  and F represent a 1-naphthyl group and a 2,3-naphtho-fused group, respectively.

24. A pharmaceutical composition according to claim 20 wherein Y represents a  $\text{CH}_3$ , or  $\text{N}(\text{Me})_2$  or  $\text{NHMe}$  or a 4-pyridine group.

25. A pharmaceutical composition according to claim 20, wherein the compounds are selected from those having the formulae:

4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,  
4-[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,  
7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,  
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,  
4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine, 7-  
[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,  
7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,  
7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine,  
7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-oxide,  
as defined herein.

26. A method of inducing apoptosis in a subject comprising administering a pharmaceutically effective amount of a compound of formula I



wherein:


(i) R<sub>1</sub> represents an unsubstituted C<sub>6</sub> or C<sub>10</sub> aryl group; or a C<sub>6</sub> aryl group substituted with

Me or OMe;

(ii) A represents O, S; or a sulfur atom oxidized to sulfoxide;

(iii) the cyclic group labeled F represents an unsubstituted C<sub>6</sub> or C<sub>10</sub> aryl or a C<sub>5</sub> heteroaryl group (nitrogen as heteroatom) or a phenyl substituted with ethoxycarbonyl function; and

(iv) Y represents the group



wherein R<sub>2</sub> and R<sub>3</sub> are independently hydrogen; or methyl or ethyl;

or Y represents the group CH<sub>3</sub>; or (CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub> or an unsubstituted C<sub>5</sub> heteroaryl group (nitrogen as heteroatom).

27. A method for inducing apoptosis in a subject comprising administering a pharmaceutically effective amount of a compound selected from those having the formulae:-

4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,

7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,

4-[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,

7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,

7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,

7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,

7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,

7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,

4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,

4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4] oxazepine, 7-

[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,


7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,

7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine,

7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-Oxide, as defined herein.


28. The method of claims 26 or 27 wherein the subject is a human or animal.

29. A method of treating cancerous tumors and other cancerous conditions in a subject comprising administering a pharmaceutically effective amount of a compound of formula I



wherein:

- (i)  $R_1$  represents an unsubstituted  $C_6$  or  $C_{10}$  aryl group; or a  $C_6$  aryl group substituted with Me or OMe;
- (ii) A represents O, S; or a sulfur atom oxidized to sulfoxide;
- (iii) the cyclic group labeled F represents an unsubstituted  $C_6$  or  $C_{10}$  aryl or a  $C_5$  heteroaryl group (nitrogen as heteroatom) or a phenyl substituted with ethoxycarbonyl function; and
- (iv) Y represents the group



wherein  $R_2$  and  $R_3$  are independently hydrogen; or methyl or ethyl;

or Y represents the group  $CH_3$ ; or  $(CH_2)_2CH_3$  or an unsubstituted  $C_5$  heteroaryl group (nitrogen as heteroatom).

30. A method of treating cancerous tumors and other cancerous conditions in a subject comprising administering a pharmaceutically effective amount of a compound selected from those having the formulae:-

4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,  
4-[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,  
7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,  
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,  
4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4] oxazepine, 7-  
[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,  
7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,  
7-Isonicotinoyloxy-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine,  
7-(Butyryloxy)-6-(p-methoxyphenyl)pyrrolo[2,1-d][1,5]benzothiazepine 5-Oxide, as defined herein.

31. The method of claims 29 or 31 wherein the subject is a human or animal.

32. A compound selected from the group consisting of:

4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,  
4-[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,  
7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,

7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,  
7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,  
4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,  
4-[(Dimethylcarbamoyl)oxy]-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4] oxazepine, 7-  
[(Ethylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,  
7-[(Methylcarbamoyl)oxy]-6-phenylpyrrolo[2,1-d][1,5]benzoxazepine,  
as defined herein.

**IN THE DRAWINGS:**

Kindly insert the enclosed replacement sheets for Figures 1, 3, 4, 8, 9, 17, 21, 22, 24, 28, 31, 32, 33, 34, 35, 36 and 37.

**REMARKS**

Claims 1-19 have been cancelled without prejudice or disclaimer. New claims 20-32 have been added. Additionally, replacement sheets are submitted for Figures 1, 3, 4, 8, 9, 17, 21, 22, 24, 28, 31, 32, 33, 34, 35, 36 and 37, merely to correct certain informalities appearing in the original figures. No new matter is added by virtue of the within amendment. For instance, support for new claims 20-32 appears throughout the specification and in the original claims of the application. In particular, see the present application at pages 3-8.

As noted in the Office Action, Applicants elected the subject matter of original claims 1-19, where A is O or S. Accordingly, claims 1-19 have been cancelled and rewritten as new claims 20-32, which claims are directed to the compounds, methods and pharmaceutical compositions of the elected subject matter only.

Claims 1-9 stand rejected under 35 USC §112, 2<sup>nd</sup> paragraph. As the rejection is